STAAR Surgical Company
1911 Walker Avenue
Monrovia
California
91016
United States
Tel: 626-303-7902
Fax: 626-303-2962
Website: http://www.staar.com/
Email: info@staar.com
342 articles about STAAR Surgical Company
-
STAAR Surgical Announces Preliminary Net Sales for First Quarter 2024
4/4/2024
STAAR Surgical Company today announced preliminary net sales for the first quarter ended March 29, 2024, are expected to be in excess of $77 million with U.S. ICL sales expected to be $5 million for the quarter.
-
STAAR Surgical Celebrates Three Million Implantable Collamer® Lenses
3/18/2024
STAAR Surgical Company, a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses for myopia, astigmatism and presbyopia, announced that more than three million ICLs have been sold globally.
-
STAAR Surgical Adds Arthur Butcher and Wei Jiang to Board of Directors
3/12/2024
STAAR Surgical Company announced the appointment of Arthur Butcher, Executive Vice President and Group President, MedSurg and Asia Pacific for Boston Scientific, and Wei Jiang, retired Executive Vice President and President of Bayer Pharmaceuticals Region China & APAC, to its Board of Directors, effective March 12, 2024.
-
STAAR Surgical to Participate in Two Upcoming March 2024 Investor Conferences
3/6/2024
STAAR Surgical Company announced that management will participate in meetings with investors at the following conferences: Oppenheimer Healthcare MedTech & Services Conference, Tuesday, March 12 Sidoti Small Cap Conference, Wednesday, March 13 Management will also meet with investors in Shenzhen and Shanghai, China, from Monday, March 18 through Wednesday, March 20.
-
STAAR Surgical Reports Fourth Quarter and Fiscal Year 2023 Results
2/26/2024
STAAR Surgical Company, a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses for myopia, astigmatism and presbyopia, reported financial results for the fourth quarter and fiscal year ended December 29, 2023.
-
STAAR Surgical to Report Fourth Quarter Results on February 26, 2024
2/19/2024
STAAR Surgical Company today announced that it will release financial results for the fourth quarter ending December 29, 2023, on Monday, February 26, 2024, after the market close.
-
STAAR Surgical Announces Strategic Agreement in U.S. with SharpeVision
1/23/2024
STAAR Surgical Company and SharpeVision announced a strategic agreement to provide EVO ICL lenses as a first choice for patients seeking visual freedom from contact lenses and glasses.
-
STAAR Surgical Announces Preliminary Results for Fourth Quarter and Fiscal 2023
1/8/2024
STAAR Surgical Company, a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses for myopia, astigmatism and presbyopia, announced preliminary results for the fourth quarter and fiscal year ended December 29, 2023.
-
Lilian Zhou Appointed to STAAR Surgical Board of Directors
12/4/2023
STAAR Surgical Company, a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses for myopia, astigmatism and presbyopia, announced the appointment of Lilian Zhou to its Board of Directors, effective December 4, 2023.
-
STAAR Surgical to Present at Stephens Annual Investment Conference (NASH2023)
11/15/2023
STAAR Surgical Company, a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses for myopia, astigmatism and presbyopia, announced that management will participate in the Stephens Annual Investment Conference on Thursday, November 16, 2023.
-
STAAR Surgical Reports Third Quarter 2023 Results
11/1/2023
STAAR Surgical Company, a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses for myopia, astigmatism and presbyopia, reported financial results for the third quarter ended September 29, 2023.
-
STAAR Surgical Celebrates 30th Anniversary of Implantable Collamer® Lens (ICL)
10/17/2023
STAAR Surgical Company, a leading developer, manufacturer and marketer of implantable lenses for the eye, is celebrating the 30th anniversary of its proprietary Implantable Collamer® Lens.
-
STAAR Surgical Teams Up With Tennessee Titans Quarterback Will Levis On Life Changing Vision Correction Procedure, EVO ICL
8/9/2023
STAAR Surgical Company today announced its partnership with Will Levis, quarterback for the Tennessee Titans of the National Football League (NFL).
-
STAAR Surgical to Participate in Upcoming Investor Conferences
8/7/2023
STAAR Surgical Company today announced that management will participate in several upcoming investor conferences.
-
STAAR Surgical Reports Second Quarter 2023 Results
8/2/2023
STAAR Surgical Company, a leading developer, manufacturer and marketer of implantable lenses for the eye, reported financial results for the second quarter ended June 30, 2023.
-
STAAR Surgical to Report Second Quarter Results on August 2, 2023
7/19/2023
STAAR Surgical Company today announced that it will release financial results for the second quarter ended June 30, 2023 on Wednesday, August 2, 2023 after the market close.
-
STAAR Surgical Reports First Quarter 2023 Results
5/3/2023
STAAR Surgical Company, a leading developer, manufacturer and marketer of implantable lenses for the eye, reported financial results for the first quarter ended March 31, 2023.
-
STAAR Surgical to Report First Quarter Results on May 3, 2023
4/19/2023
STAAR Surgical Company today announced that it will release financial results for the first quarter ended March 31, 2023 on Wednesday, May 3, 2023 after the market close.
-
STAAR Surgical Names Warren Foust Chief Operating Officer; Magda Michna, Ph.D., Chief Clinical, Regulatory and Medical Affairs Officer
3/29/2023
STAAR Surgical Company today announced Warren Foust has been named Chief Operating Officer and Magda Michna, Ph.D., has been named Chief Clinical, Regulatory and Medical Affairs Officer.
-
STAAR Surgical Reports Fourth Quarter and Fiscal Year 2022 Results
2/21/2023
STAAR Surgical Company, a leading developer, manufacturer and marketer of implantable lenses for the eye, reported financial results for the fourth quarter and fiscal year ended December 30, 2022.